Re-Imagining Drug Safety Powered by Genomics, Information Integration and Emerging Technologies

tata consultancy services, tcs, drug safety, genomics, technology

The global healthcare environment is undergoing transformation across the care delivery eco-system to provide more affordable and quality healthcare to all. The paper focusses on the next-generation drug safety models, and outlines the direction for realizing the emerging vision.

Scientific advancements, emerging technologies and availability of large amount of information from different sources are offering newer opportunities for modernizing drug safety. In parallel, the pharmacovigilance regulatory landscape is also shifting to ensure improved safety for patients. This is the time to reimagine the drug safety sector to transform it into an advanced, proactive and patient-centric practice.

In addition to internalizing regulatory direction and expectations, the drug safety sector needs to focus on three core areas: genomics, information integration and emerging technologies. Each of these areas can unlock new frontiers to further improve patient safety. This paper presents thoughts on the future of drug safety and describes a TCS 5I model of drug safety:

Integrate: Constantly integrate information and insights needed for drug safety and be a custodian of all safety related knowledge

Inquire: Collaborating with R&D for capturing safety related insights and executing safety studies throughout the life cycle of the drugs

Identify: Perform advance analytics to predict and identify safety concerns early

Improve: Proactively address safety concerns via risk management practices

Inform: Devise safety communication strategy (including safety education to the stakeholders such as physicians, patients and care givers) and perform regulatory interactions

Aligning to the perspectives described in this paper, there is a strong need to develop next-generation drug safety platforms. Thorough drug safety domain insights combined with cutting-edge technology leadership capabilities can realize this patient-centric integrated drug safety vision.

Download whitepaper

Tata Consultancy Services will be joining the World Drug Safety Congress Europe 2014 as Platinum Sponsor, this 10-11 September in London.  To find out more, click here